Namodenoson Treatment of Advanced Pancreatic Cancer

This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.

Trial Details

NCT ID

NCT06387342

Phase

PHASE2

Sponsor

Can-Fite BioPharma

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Namodenoson 25mg

Locations (sample)

Petah Tikva, Israel|32.08707,34.88747

Key Eligibility Criteria

Males and females at least 18 years of age.
Histologically or cytologically confirmed pancreatic adenocarcinoma, or clinically diagnosed based upon scan results and a serum Cancer Antigen 19-…
Pancreatic adenocarcinoma is advanced (i.e., treatment-refractory or metastatic) and no standard therapies are expected to be curative.
Pancreatic adenocarcinoma has progressed on at least 1 prior systemic treatment regimen, or the patient refuses standard treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →